(Brussels) The European Commission announced on Thursday that it has reached an agreement with the US pharmaceutical group Gilead to supply 500,000 doses of remdesivir, an antiviral agent approved in the EU to treat patients with COVID-19.
Posted Oct 8, 2020 at 7:16 am
"Today we ensure access to remdesivir for the treatment of 500,000 patients who need it," Stella Kyriakides, health commissioner, said in a statement.
“Thanks to our common public procurement markets, we give European countries the means to join forces and access essential equipment and medicines,” she explains.
The Gilead Group produces Veklury, the brand remdesivir. The agreement announced by Ms. Kyriakides provides for the ability to increase the supply to more than 500,000 doses.
All EU countries, member states of the European Economic Area, the United Kingdom and six candidate countries (Albania, North Macedonia, Montenegro, Serbia, Kosovo and Bosnia-Herzegovina) benefit from these purchases.
"Veklury is at this stage the only drug to receive conditional marketing authorization in the EU for the treatment of patients in need of oxygen," says the European Commission.
A previous contract with the US group has enabled the distribution of 33,380 Veklury treatments in the EU and UK since August, the Commission said.